Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Starmer says UK to recognize Palestinian state if...
‘Critical’ closed-door congressional huddle focuses on growing antisemitism...
Trump’s CDC pick confirmed—but her pro-vaccine stance may...
Trump pick Emil Bove confirmed as federal judge...
From Gaza to Greenland, Macron breaks with Trump...
Schumer calls on FBI to conduct counterintelligence threat...
Biden ‘Politburo’ member Steve Ricchetti to appear before...
Trump looks to skip G20 summit in South...
Backlash against Sydney Sweeney ‘jeans/genes’ ad gets mocked...
Biden ‘Politburo’ member Steve Ricchetti appears before House...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Zero Candida Technologies:Pioneering Technology-driven, Innovative Solution for Non-drug Treatment of Candidiasis

by admin December 18, 2024
December 18, 2024
Zero Candida Technologies:Pioneering Technology-driven, Innovative Solution for Non-drug Treatment of Candidiasis

Founded by a team of seasoned entrepreneurs and healthcare experts, Zero Candida (TSXV:ZCT) is a fem-tech pioneer, combining advanced artificial intelligence with non-drug diagnostics and personalized treatment modalities in a single device. The company developed an innovative, first-of-its-kind solution to the diagnosis and treatment of Candidiasis, a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva. The device offers precision therapy by eliminating fungal infections with over 99.99 percent effectiveness in just three hours, a revolutionary improvement over existing treatments.

Zero Candida is on track to complete clinical trials and file for FDA approval in 2024 with its innovative technology.

Zero Candida’s SMART vaginal diagnostic device utilizes blue light therapy to treat this widespread condition without drugs. This non-drug therapy addresses key issues associated with conventional antifungal medications, including reduced risk of drug resistance, minimized side effects, and potential for faster symptom relief

Company Highlights

  • Zero Candida Technologies is a fem-tech company focused on developing a SMART diagnostic and therapeutic device aimed at eliminating vaginal candidiasis (commonly known as yeast infection), a condition that affects three out four women globally.
  • Candidiasis a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva. In several cases, the current treatment for Candidiasis has been ineffective.
  • Zero Candida has completed proof-of-concept studies, and demonstrated near-complete fungal eradication with over 99.99 percent effectiveness in just three hours.
  • Founded by a team of experienced entrepreneurs and healthcare experts, the company is addressing the significant unmet needs of the women’s health market.
  • The fem-tech segment of the med tech market is expected to grow at a CAGR of 18.2 percent and is estimated to reach nearly US$30 billion by 2032. North America dominated the global fem-tech market with a share of 52.91 percent in 2023.
  • The company has already patented this technology in South Africa, while additional filings for patent application in the US and EU are underway.

This Zero Candida profile is part of a paid investor education campaign.*

Click here to connect with Zero Candida (TSXV:CZT) to receive an Investor Presentation

This post appeared first on investingnews.com

previous post
Women’s basketball league Unrivaled secures $28M in funding from star-studded investor lineup
next post
First Helium Provides Year End Corporate Update

You may also like

Awalé Selected to Exhibit at PDAC Core Shack,...

February 25, 2025

AME: Supreme Court of Western Australia approves Scheme

November 29, 2024

Charbone Hydrogene annonce la date d’interconnexion au reseau...

January 15, 2025

White Cliff Minerals Limited (ASX: WCN) – Trading...

October 14, 2024

Microsoft Plans to Reduce Kernel-level Operations for Cybersecurity...

September 18, 2024

Emyria and UWA in Partnership to Commercialise Novel...

October 31, 2024

2025 Crypto Market: Q2 Review and Forecast

July 9, 2025

Bitcoin Well Announces Nostr Integration; Including Bitcoin Purchases...

May 27, 2025

Tartana Proposes to Acquire Critical Minerals Project Portfolio

October 10, 2024

Stallion Uranium Announces Failure to File Cease Trade...

May 14, 2025

Recent Posts

  • Starmer says UK to recognize Palestinian state if Israel doesn’t agree to ceasefire, Hamas must ‘disarm’
  • ‘Critical’ closed-door congressional huddle focuses on growing antisemitism in US, Mamdani’s rise
  • Trump’s CDC pick confirmed—but her pro-vaccine stance may clash with RFK Jr.’s agenda
  • Trump pick Emil Bove confirmed as federal judge after furious Democrat walkout, whistleblower complaints
  • From Gaza to Greenland, Macron breaks with Trump on global flashpoints

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (845)
    • Investing (2,651)
    • Politics (3,267)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.